Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTX MC 138

Next Previous
Drug Profile

TTX MC 138

Alternative Names: TTX-MC-138

Latest Information Update: 12 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransCode Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
  • Mechanism of Action Cell death stimulants; Gene silencing; MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Colorectal cancer; Glioblastoma; Osteosarcoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Unspecified

Most Recent Events

  • 06 Jan 2026 TTX MC 138 is still in Preclinical trials for Glioblastoma in the US
  • 06 Jan 2026 Pharmacodynamics data from a preclinical study in Glioblastoma released by TransCode Therapeutics
  • 28 Dec 2025 No recent reports of development identified for preclinical development in Glioblastoma in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top